Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis

[1] Danaei G(2011)National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 31-40

[2] Finucane MM(2012)Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 1364-1379

[3] Lu Y(2011)Management of type 2 diabetes: new and future developments in treatment Lancet 378 182-197

[4] Inzucchi SE(2007)Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care Diabet Med 24 350-358

[5] Bergenstal RM(2010)Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus Drugs 70 377-385

[6] Buse JB(2010)Sodium glucose co-transporter 2 inhibitors as a new treatment for diabetes mellitus J Clin Endocrinol Metab 95 34-42

[7] Tahrani AA(2005)Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes Diabetes 54 3427-3434

[8] Bailey CJ(2010)Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabet Med 27 136-142

[9] Del Prato S(2013)Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus Expert Opin Drug Metab Toxicol 9 763-775

[10] Cook MN(2013)The clinical efficacy and safety of sodium glucose co-transporter 2 inhibitors in adults with type 2 diabetes mellitus Pharmacotherapy 33 984-999

[1] Danaei G(2011)National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants Lancet 378 31-40

[2] Finucane MM(2012)Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 1364-1379

[3] Lu Y(2011)Management of type 2 diabetes: new and future developments in treatment Lancet 378 182-197

[4] Inzucchi SE(2007)Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care Diabet Med 24 350-358

[5] Bergenstal RM(2010)Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus Drugs 70 377-385

[6] Buse JB(2010)Sodium glucose co-transporter 2 inhibitors as a new treatment for diabetes mellitus J Clin Endocrinol Metab 95 34-42

[7] Tahrani AA(2005)Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes Diabetes 54 3427-3434

[8] Bailey CJ(2010)Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabet Med 27 136-142

[9] Del Prato S(2013)Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus Expert Opin Drug Metab Toxicol 9 763-775

[10] Cook MN(2013)The clinical efficacy and safety of sodium glucose co-transporter 2 inhibitors in adults with type 2 diabetes mellitus Pharmacotherapy 33 984-999